Known targets — ChEMBL curated mechanism
KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2
The experimentally established mechanism targets of Guanidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.61 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanidine SCHEMBL11252247 | 1.00 | CA5A (0.61) | CA5ACA5BALDH1A1HPGDHIF1A | |
| Guanidine SCHEMBL1013287 | 1.00 | CA5A (0.61) | CA5ACA5BALDH1A1HPGDHIF1A | |
| Guanidine SCHEMBL27574673 | 1.00 | CA5A (0.61) | CA5ACA5BALDH1A1HPGDHIF1A | |
| Guanidine SCHEMBL21392 | 1.00 | — | — | |
| Guanidine SCHEMBL17844261 | 1.00 | CA5A (0.61) | CA5ACA5BALDH1A1HPGDHIF1A | |
| Guanidine SCHEMBL6384671 | 1.00 | CA5A (0.61) | CA5ACA5BALDH1A1HPGDHIF1A | |
| Guanidine SCHEMBL8852023 | 1.00 | CA5A (0.61) | CA5ACA5BALDH1A1HPGDHIF1A | |
| Guanidine SCHEMBL4613000 | 0.96 | — | — | |
| Guanidine SCHEMBL28603290 | 0.96 | CA5A (0.57) | CA5ACA5BALDH1A1HPGDHIF1A | |
| Guanidine SCHEMBL27704650 | 0.96 | CA5A (0.57) | CA5ACA5BALDH1A1HPGDHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937696-A1 | PROCESS FOR THE SYNTHESIS OF HMG-CoA REDUCTASE INHIBITORS | LEK Pharmaceuticals D.D. (SI) | 2008-07-02 | — | — | EP | claimed |
| EP-1775299-A1 | Process for the synthesis of HMG-CoA reductase inhibitors | LEK Pharmaceuticals D.D. (SI) | 2007-04-18 | — | — | EP | claimed |
| WO-2007039287-A1 | PROCESS FOR THE SYNTHESIS OF HMG-CoA REDUCTASE INHIBITORS | LEK PHARMACEUTICALS D.D. (SI) | 2007-04-12 | — | — | WO | claimed |
| CN-108069880-A | A kind of polyhexamethylene list guanidine nitrate preparation method | 辽宁科技大学 | 2018-05-25 | — | — | CN | disclosed |
| US-9885082-B2 | Embodiments of a probe and method for targeting nucleic acids | UNIVERSITY OF IDAHO (US) | 2018-02-06 | — | — | US | disclosed |
| US-9446109-B2 | Glycoconjugates and their use as potential vaccines against infection by Shigella flexneri | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-09-20 | — | — | US | disclosed |
| EP-2464651-B1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2016-04-20 | — | — | EP | disclosed |
| EP-2266978-B1 | Novel physiologically active substances | EISAI R&D MAN CO LTD (JP) | 2015-05-20 | — | — | EP | disclosed |
| EP-1548121-B1 | Physiologically active substances | EISAI R&D MAN CO LTD (JP) | 2015-04-29 | — | — | EP | disclosed |
| US-8933073-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2015-01-13 | — | — | US | disclosed |
| US-8865662-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20060264387-A1 | Macrolides | BASILEA PHARMACEUTICA AG (CH) | 2006-11-23 | — | — | US | disclosed |
| US-20060241171-A1 | Novel physiologically active substances | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2006-10-26 | — | — | US | disclosed |
| WO-2006084410-A1 | NEW MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2006-08-17 | — | — | WO | disclosed |
| EP-1642132-A2 | GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI | INSTITUT PASTEUR (FR) | 2006-04-05 | — | — | EP | disclosed |
| US-20060009439-A1 | Novel physiologically active substances | MERCIAN CORPORATION (JP) | 2006-01-12 | — | — | US | disclosed |
| US-20050245514-A1 | Novel physiologically active substances | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1548121-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | MERCIAN CORPORATION (JP) | 2005-06-29 | — | — | EP | disclosed |
| EP-1508570-A1 | NOVEL PHYSIOLGICALLY ACTIVE SUBSTANCES | MERCIAN CORPORATION (JP) | 2005-02-23 | — | — | EP | disclosed |
| WO-2005003775-A2 | GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI | INSTITUT PASTEUR (FR) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245514-A1 | Novel physiologically active substances | HIF1A, HIF1AN, VEGFA | CA5A 150/4885CA5B 258/4885ALDH1A1 133/4885 |
| US-20060264387-A1 | Macrolides | PPME1, MGAM, SMPD1 | CA5A 1670/4885CA5B 1783/4885ALDH1A1 3507/4885 |
| US-20060241171-A1 | Novel physiologically active substances | HIF1A, HIF1AN, VEGFA | CA5A 140/4885CA5B 259/4885ALDH1A1 108/4885 |
| US-20060009439-A1 | Novel physiologically active substances | HIF1A, HIF1AN, VEGFA | CA5A 140/4885CA5B 259/4885ALDH1A1 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.